Preclinical and clinical studies on cytokine-induced killer cells for the treatment of renal cell carcinoma

Archives of Pharmacal Research

Volumn 37, Issue 5, 2014, Pages 559-566

  Kim, Ji Sung ^a   Chung, In Sung ^a   Lim, Sang Hee ^a   Park, Yunsoo ^a   Park, Mi Jeong ^a   Kim, Ju Young ^a   Kim, Yong Guk ^a   Hong, Jin Tae ^a   Kim, Youngsoo ^a   Han, Sang Bae ^a  

^a Chungbuk National University   (South Korea)

Author keywords

Clinical study; Cytokine induced killer cells; Preclinical study; Renal cell carcinoma

Indexed keywords

ANTINEOPLASTIC ACTIVITY; CANCER MODEL; CANCER PATIENT; CYTOKINE INDUCED KILLER CELL; EX VIVO STUDY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; LYMPHOCYTE ACTIVATION; NUDE MOUSE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR XENOGRAFT; ANIMAL; CARCINOMA, RENAL CELL; DRUG SCREENING; IMMUNOLOGY; IMMUNOTHERAPY; KIDNEY NEOPLASMS; MOUSE; PATHOLOGY; PROCEDURES; TRANSPLANTATION;

ANIMALS; CARCINOMA, RENAL CELL; CYTOKINE-INDUCED KILLER CELLS; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; MICE; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901261692     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-014-0381-x     Document Type: Review

References (62)

1. Alvarnas, J.C., Y.C. Linn, E.G. Hope, and R.S. Negrin. 2001. Expansion of cytotoxic CD3 + CD56 + cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation 7: 216-222. (Pubitemid 32433248)
2. Bukowski, R.M., W. Sharfman, S. Murthy, P. Rayman, R. Tubbs, J. Alexander, G.T. Budd, J.S. Sergi, L. Bauer, V. Gibson, et al. 1991. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma. Cancer Research 51: 4199-4205.
3. Conti, A., M. Santoni, C. Amantini, L. Burattini, R. Berardi, G. Santoni, S. Cascinu, and G. Muzzonigro. 2013. Progress of molecular targeted therapies for advanced renal cell carcinoma. Biomed Research International 2013: 419176.
4. Dillman, R., P. Schiltz, C. Depriest, N. Barth, L. Beutel, C. De Leon, A. O'connor, and S. Nayak. 2004. Tumor-infiltrating lymphocytes and interleukin-2: Dose and schedules of administration in the treatment of metastatic cancer. Cancer Biotherapy and Radiopharmaceuticals 19: 730-737. (Pubitemid 40279581)
5. Eisen, T., C.N. Sternberg, C. Robert, P. Mulders, L. Pyle, S. Zbinden, H. Izzedine, and B. Escudier. 2012. Targeted therapies for renal cell carcinoma: Review of adverse event management strategies. Journal of the National Cancer Institute 104: 93-113.
6. Escudier, B., T. Eisen, C. Porta, J.J. Patard, V. Khoo, F. Algaba, P. Mulders, V. Kataja, and E.G.W. Group. 2012. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 23(Suppl 7): vii65-vii71.
7. Escudier, B., T. Eisen, W.M. Stadler, C. Szczylik, S. Oudard, M. Staehler, S. Negrier, C. Chevreau, A.A. Desai, F. Rolland, T. Demkow, T.E. Hutson, M. Gore, S. Anderson, G. Hofilena, M. Shan, C. Pena, C. Lathia, and R.M. Bukowski. 2009. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. Journal of Clinical Oncology 27: 3312-3318.
8. Escudier, B., A. Pluzanska, P. Koralewski, A. Ravaud, S. Bracarda, C. Szczylik, C. Chevreau, M. Filipek, B. Melichar, E. Bajetta, V. Gorbunova, J.O. Bay, I. Bodrogi, A. Jagiello-Gruszfeld, N. Moore, and A.T. Investigators. 2007. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. The Lancet 370: 2103-2111. (Pubitemid 350296300)
9. Figlin, R.A., I. Kaufmann, and J. Brechbiel. 2013. Targeting PI3 K and mTORC2 in metastatic renal cell carcinoma: New strategies for overcoming resistance to VEGFR and mTORC1 inhibitors. International Journal of Cancer 133: 788-796.
10. Figlin, R.A., J.A. Thompson, R.M. Bukowski, N.J. Vogelzang, A.C. Novick, P. Lange, G.D. Steinberg, and A.S. Belldegrun. 1999. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. Journal of Clinical Oncology 17: 2521-2529. (Pubitemid 29368254)
11. Franceschetti, M., A. Pievani, G. Borleri, L. Vago, K. Fleischhauer, J. Golay, and M. Introna. 2009. Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. Experimental Hematology 37: 616-628. e612.
12. Goedegebuure, P.S., L.M. Douville, H. Li, G.C. Richmond, D.D. Schoof, M. Scavone, and T.J. Eberlein. 1995. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: A pilot study. Journal of Clinical Oncology 13: 1939-1949.
13. Hartmann, J.T., and C. Bokemeyer. 1999. Chemotherapy for renal cell carcinoma. Anticancer Research 19: 1541-1543. (Pubitemid 29255643)
14. Hoffman, D.M., B.J. Gitlitz, A. Belldegrun, and R.A. Figlin. 2000. Adoptive cellular therapy. Seminars in Oncology 27: 221-233. (Pubitemid 30205377)
15. Hudes, G.R. 2009. Targeting mTOR in renal cell carcinoma. Cancer 115: 2313-2320.
16. Jemal, A., F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman. 2011. Global cancer statistics. CA: A Cancer Journal for Clinicians 61: 69-90.
17. Kane, C.J., K. Mallin, J. Ritchey, M.R. Cooperberg, and P.R. Carroll. 2008. Renal cell cancer stage migration: Analysis of the National Cancer Data Base. Cancer 113: 78-83. (Pubitemid 351976389)
18. Kim, H.M., J.S. Kang, J. Lim, S.K. Park, K. Lee, Y.D. Yoon, C.W. Lee, K.H. Lee, G. Han, K.H. Yang, Y.J. Kim, Y. Kim, and S.B. Han. 2007. Inhibition of human ovarian tumor growth by cytokine-induced killer cells. Archives of Pharmacal Research 30: 1464-1470.
19. Kradin, R.L., J.T. Kurnick, D.S. Lazarus, F.I. Preffer, S.M. Dubinett, C.E. Pinto, J. Gifford, E. Davidson, B. Grove, R.J. Callahan, et al. 1989. Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. The Lancet 1: 577-580. (Pubitemid 19074003)
20. Liu, L., W. Zhang, X. Qi, H. Li, J. Yu, S. Wei, X. Hao, and X. Ren. 2012. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clinical Cancer Research 18: 1751-1759.
21. Liu, P., L. Chen, and X. Huang. 2009. The antitumor effects of CIK cells combined with docetaxel against drug-resistant lung adenocarcinoma cell line SPC-A1/DTX in vitro and in vivo. Cancer Biotherapy Radiopharmaceuticals 24: 91-98.
22. Lotze, M.T., E.A. Grimm, A. Mazumder, J.L. Strausser, and S.A. Rosenberg. 1981. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Research 41: 4420-4425. (Pubitemid 12201351)
23. Mcdermott, D.F., M.M. Regan, J.I. Clark, L.E. Flaherty, G.R. Weiss, T.F. Logan, J.M. Kirkwood, M.S. Gordon, J.A. Sosman, M.S. Ernstoff, C.P. Tretter, W.J. Urba, J.W. Smith, K.A. Margolin, J.W. Mier, J.A. Gollob, J.P. Dutcher, and M.B. Atkins. 2005. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 23: 133-141. (Pubitemid 41702632)
24. Motzer, R.J., N. Agarwal, C. Beard, S. Bhayani, G.B. Bolger, M.A. Carducci, S.S. Chang, T.K. Choueiri, S.L. Hancock, G.R. Hudes, E. Jonasch, D. Josephson, T.M. Kuzel, E.G. Levine, D.W. Lin, K.A. Margolin, M.D. Michaelson, T. Olencki, R. Pili, T.W. Ratliff, B.G. Redman, C.N. Robertson, C.J. Ryan, J. Sheinfeld, P.E. Spiess, J. Wang, R.B. Wilder, and National Comprehensive Cancer N. 2011. Kidney cancer. Journal of the National Comprehensive Cancer Network 9: 960-977.
25. Motzer, R.J., T.E. Hutson, P. Tomczak, M.D. Michaelson, R.M. Bukowski, S. Oudard, S. Negrier, C. Szczylik, R. Pili, G.A. Bjarnason, X. Garcia-Del-Muro, J.A. Sosman, E. Solska, G. Wilding, J.A. Thompson, S.T. Kim, I. Chen, X. Huang, and R.A. Figlin. 2009. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 27: 3584-3590.
26. Mule, J.J., S. Shu, S.L. Schwarz, and S.A. Rosenberg. 1984. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225: 1487-1489. (Pubitemid 14033135)
27. Nagashima, Y., N. Kuroda, and M. Yao. 2013. Transition of organizational category on renal cancer. Japanese Journal of Clinical Oncology 43: 233-242.
28. Ochoa, A.C., G. Gromo, B.J. Alter, P.M. Sondel, and F.H. Bach. 1987. Long-term growth of lymphokine-activated killer (LAK) cells: Role of anti-CD3, beta-IL 1, interferon-gamma and -beta. The Journal of Immunology 138: 2728-2733. (Pubitemid 17051856)
29. Parkhurst, M.R., J.P. Riley, M.E. Dudley, and S.A. Rosenberg. 2011. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clinical Cancer Research 17: 6287-6297.
30. Pievani, A., G. Borleri, D. Pende, L. Moretta, A. Rambaldi, J. Golay, and M. Introna. 2011. Dual-functional capability of CD3 + CD56 + CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood 118: 3301-3310.
31. Rasmussen, N., and W.K. Rathmell. 2011. Looking beyond inhibition of VEGF/mTOR: Emerging targets for renal cell carcinoma drug development. Current Clinical Pharmacology 6: 199-206.
32. Restifo, N.P., M.E. Dudley, and S.A. Rosenberg. 2012. Adoptive immunotherapy for cancer: Harnessing the T cell response. Nature Reviews Immunology 12: 269-281.
33. Rini, B.I., and M.B. Atkins. 2009. Resistance to targeted therapy in renal-cell carcinoma. The Lancet Oncology 10: 992-1000.
34. Rosenberg, S.A., M.T. Lotze, L.M. Muul, S. Leitman, A.E. Chang, S.E. Ettinghausen, Y.L. Matory, J.M. Skibber, E. Shiloni, J.T. Vetto, et al. 1985a. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. New England Journal of Medicine 313: 1485-1492. (Pubitemid 16212345)
35. Rosenberg, S.A., M.T. Lotze, J.C. Yang, S.L. Topalian, A.E. Chang, D.J. Schwartzentruber, P. Aebersold, S. Leitman, W.M. Linehan, C.A. Seipp, et al. 1993. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. Journal of the National Cancer Institute 85: 622-632. (Pubitemid 23120507)
36. Rosenberg, S.A., J.J. Mule, P.J. Spiess, C.M. Reichert, and S.L. Schwarz. 1985b. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. Journal of Experimental Medicine 161: 1169-1188. (Pubitemid 15011332)
37. Scelo, G., and P. Brennan. 2007. The epidemiology of bladder and kidney cancer. Nature Clinical Practice Urology 4: 205-217. (Pubitemid 46567153)
38. Schmidt-Wolf, G.D., R.S. Negrin, and I.G. Schmidt-Wolf. 1997. Activated T cells and cytokine-induced CD3 + CD56 + killer cells. Annals of Hematology 74: 51-56. (Pubitemid 27095476)
39. Schmidt-Wolf, I.G., S. Finke, B. Trojaneck, A. Denkena, P. Lefterova, N. Schwella, H.G. Heuft, G. Prange, M. Korte, M. Takeya, T. Dorbic, A. Neubauer, B. Wittig, and D. Huhn. 1999. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. British Journal of Cancer 81: 1009-1016. (Pubitemid 29516145)
40. Schmidt-Wolf, I.G., P. Lefterova, V. Johnston, C. Scheffold, M. Csipai, B.A. Mehta, T. Tsuruo, D. Huhn, and R.S. Negrin. 1996. Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells. Cellular Immunology 169: 85-90.
41. Schmidt-Wolf, I.G., R.S. Negrin, H.P. Kiem, K.G. Blume, and I.L. Weissman. 1991. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. Journal of Experimental Medicine 174: 139-149.
42. Sternberg, C.N., I.D. Davis, J. Mardiak, C. Szczylik, E. Lee, J. Wagstaff, C.H. Barrios, P. Salman, O.A. Gladkov, A. Kavina, J.J. Zarba, M. Chen, L. Mccann, L. Pandite, D.F. Roychowdhury, and R.E. Hawkins. 2010. Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. Journal of Clinical Oncology 28: 1061-1068.
43. Tamaskar, I., J. Dhillon, and R. Pili. 2011. Resistance to angiogenesis inhibitors in renal cell carcinoma. Clinical Advances in Hematology and Oncology 9: 101-110.
44. Thanendrarajan, S., Y. Kim, and I. Schmidt-Wolf. 2012. New adoptive immunotherapy strategies for solid tumours with CIK cells. Expert Opinion on Biological Therapy 12: 565-572.
45. Thiounn, N., C. Mathiot, T. Flam, E. Tartour, C. Peyret, I. Joyeux, J.P. Abecassis, M. Zerbib, W.H. Fridman, and B. Debre. 1994. CD4 TIL (Tumor Infiltrating Lymphocytes) induce complete response in patients treated with IL-2 (Interleukin-2). Preliminary study. Journal of Urology (Paris) 100: 185-188. (Pubitemid 24350208)
46. Thompson, J.A., D.J. Lee, C.G. Lindgren, L.A. Benz, C. Collins, W.P. Shuman, D. Levitt, and A. Fefer. 1989. Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells. Cancer Research 49: 235-240. (Pubitemid 19024438)
47. Tomita, Y., A. Katagiri, K. Saito, T. Imai, T. Saito, T. Tanikawa, M. Terunuma, T. Nishiyama, and K. Takahashi. 1998. Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: Long-term results. International Journal of Urology 5: 16-21. (Pubitemid 28097225)
48. Topalian, S.L., D. Solomon, F.P. Avis, A.E. Chang, D.L. Freerksen, W.M. Linehan, M.T. Lotze, C.N. Robertson, C.A. Seipp, P. Simon, et al. 1988. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: A pilot study. Journal of Clinical Oncology 6: 839-853.
49. Verneris, M.R., J. Baker, M. Edinger, and R.S. Negrin. 2002. Studies of ex vivo activated and expanded CD8 + NK-T cells in humans and mice. Journal of Clinical Immunology 22: 131-136. (Pubitemid 34596936)
50. Verneris, M.R., M. Karami, J. Baker, A. Jayaswal, and R.S. Negrin. 2004. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8 + T cells. Blood 103: 3065-3072. (Pubitemid 38451682)
51. Wang, H., F.J. Zhou, Q.J. Wang, Z.K. Qin, L.X. Huang, Z.W. Liu, H. Han, Y.Q. Li, S.P. Chen, and J.C. Xia. 2006. Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma - A report of ten cases. Ai Zheng 25: 625-630.
52. Wang, Z., Y. Zhang, Y. Liu, L. Wang, L. Zhao, T. Yang, C. He, Y. Song, and Q. Gao. 2014. Association of myeloid-derived suppressor cells and efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma patients. Journal of Immunotherapy 37: 43-50.
53. Wersall, P., and H. Mellstedt. 1995. Increased LAK and T cell activation in responding renal cell carcinoma patients after low dose cyclophosphamide, IL-2 and alpha-IFN. Medical Oncology 12: 69-77.
54. Wu, R., M.A. Forget, J. Chacon, C. Bernatchez, C. Haymaker, J.Q. Chen, P. Hwu, and L.G. Radvanyi. 2012. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: Current status and future outlook. Cancer Journal 18: 160-175.
55. Yang, J.C., R.M. Sherry, S.M. Steinberg, S.L. Topalian, D.J. Schwartzentruber, P. Hwu, C.A. Seipp, L. Rogers-Freezer, K.E. Morton, D.E. White, D.J. Liewehr, M.J. Merino, and S.A. Rosenberg. 2003. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. Journal of Clinical Oncology 21: 3127-3132. (Pubitemid 46606294)
56. Yu, J., W. Zhang, H. Jiang, H. Li, S. Cao, and X. Ren. 2008. CD4 + T cells in CIKs (CD4 + CIKs) reversed resistance to fas-mediated apoptosis through CD40/CD40L ligation rather than IFN-gamma stimulation. Cancer Biotherapy and Radiopharmaceuticals 23: 342-354. (Pubitemid 351931461)
57. Zhan, H.L., X. Gao, X.Y. Pu, W. Li, Z.J. Li, X.F. Zhou, and J.G. Qiu. 2012. A randomized controlled trial of postoperative tumor lysate-pulsed dendritic cells and cytokine-induced killer cells immunotherapy in patients with localized and locally advanced renal cell carcinoma. Chinese Medical Journal (England) 125: 3771-3777.
58. Zhang, S., S.J. Jiang, C.Q. Zhang, H.M. Wang, and C.X. Bai. 2005a. Antitumour activities of cytokine-induced killer cells and dendritic cells in vitro and in vivo. Chinese Medical Journal (England) 118: 1308-1312.
59. Zhang, Y., J. Wang, Y. Wang, X.C. Lu, H. Fan, Y. Liu, Y. Zhang, K.C. Feng, W.Y. Zhang, M.X. Chen, X. Fu, and W.D. Han. 2013. Autologous CIK cell immunotherapy in patients with renal cell carcinoma after radical nephrectomy. Clinical and Development Immunology 2013: 195691.
60. Zhang, Y.S., F.J. Yuan, G.F. Jia, J.F. Zhang, L.Y. Hu, L. Huang, J. Wang, and Z.Q. Dai. 2005b. CIK cells from patients with HCC possess strong cytotoxicity to multidrug-resistant cell line Bel- 7402/R. World Journal of Gastroenterology 11: 3339-3345. (Pubitemid 40873236)
61. Zhao, Q., H. Zhang, Y. Li, J. Liu, X. Hu, and L. Fan. 2010. Antitumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro. Journal of Experiment and Clinical Cancer Research 29: 118.
62. Zhu, H.H., K.L. Xu, X.Y. Pan, J.Q. Liu, F.X. Chen, and Y.H. Huang. 2003. Specific anti-leukemic cell effect mediated by dendritic cells pulsed with chronic myelogenous leukemia lysate antigen in vitro. Zhongguo Shi Yan Xue Ye Xue Za Zhi 11: 278-281.